IRON — Disc Medicine, Inc. Stock Price, Chart & AI Report

Negative Oct 5, 2026 • 23:28 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. The firm is preparing a class action lawsuit to recover investor losses.

IRON securities class action FDA Complete Response Letter bitopertin program new drug application stock price decline investor losses shareholder litigation

Sentiment note

The company received an FDA Complete Response Letter denying approval of its bitopertin NDA due to uncertainties requiring additional evidence. This regulatory setback resulted in a 22% stock price decline and triggered securities litigation, indicating significant negative impact on shareholder value and company prospects.

Negative Sep 22, 2026 • 23:36 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, citing uncertainties requiring additional evidence. The stock fell 22% following the announcement. Investors who suffered losses are encouraged to join a prospective class action.

IRON FDA Complete Response Letter securities class action bitopertin program stock price decline investor losses misleading business information

Sentiment note

The company received an FDA Complete Response Letter denying approval of its new drug application for bitopertin, indicating regulatory setback and uncertainty. The stock price fell 22% on the news, and the company is now subject to securities litigation investigation for allegedly issuing materially misleading information to investors.

Negative Sep 12, 2026 • 17:47 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter rejecting the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused Disc Medicine's stock to plummet 22%. The firm is preparing a class action lawsuit to recover investor losses.

IRON FDA rejection Complete Response Letter bitopertin securities class action stock price decline investor losses drug approval

Sentiment note

The company received an FDA Complete Response Letter rejecting its new drug application for bitopertin, indicating the drug cannot be approved without additional evidence. This regulatory setback resulted in a 22% stock price decline and triggered securities litigation, representing a significant negative development for the company and its investors.

Negative Sep 4, 2026 • 21:26 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Disc Medicine, Inc. (NASDAQ: IRON) received a Complete Response Letter from the FDA on February 13, 2026, rejecting its bitopertin drug application due to uncertainties requiring additional evidence. The stock fell 22% following the announcement. Rosen Law Firm is investigating potential securities fraud claims and preparing a class action lawsuit on behalf of affected shareholders.

IRON FDA rejection Complete Response Letter bitopertin securities class action stock price decline investor losses

Sentiment note

The company received an FDA rejection for its lead drug candidate (bitopertin), resulting in a 22% stock price decline. This represents a significant setback for the company's pipeline and has triggered securities litigation, indicating material harm to shareholder value.

Positive Sep 2, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine (NASDAQ: IRON), a clinical-stage biopharmaceutical company focused on hematologic diseases, announced participation in four major investor conferences in September 2026. The company also reported completing a Type A FDA meeting on bitopertin with Phase 3 APOLLO study data expected in Q4 2026, which could serve as the basis for a Complete Response Letter (CRL) response.

IRON biopharmaceutical hematologic diseases FDA meeting Phase 3 clinical trial investor conferences bitopertin red blood cell biology

Sentiment note

The company achieved a successful Type A FDA meeting on bitopertin with alignment that Phase 3 data can support CRL response, indicating regulatory progress. Multiple investor conference presentations demonstrate investor engagement and confidence. Expected Phase 3 topline data in Q4 2026 represents a near-term catalyst for the company.

Positive Aug 31, 2026 • 22:00 UTC GlobeNewswire Inc. • Na

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Disc Medicine announced it will present clinical data from multiple programs at the SOHO 2026 Annual Meeting in Houston, including initial Phase 2 RESTORE-PV trial data for DISC-3405 in polycythemia vera patients and efficacy data from the RALLY-MF trial of DISC-0974 for myelofibrosis-associated anemia. The oral presentations are scheduled for September 9-12, 2026.

IRON Disc Medicine SOHO 2026 DISC-3405 polycythemia vera RESTORE-PV trial DISC-0974 myelofibrosis

Sentiment note

The company is presenting initial clinical data from Phase 2 trials for two investigational drug candidates at a major medical conference, demonstrating progress in their clinical-stage portfolio. The announcement highlights advancement in their myeloproliferative neoplasm programs and commitment to addressing unmet medical needs, which are positive indicators for pipeline development.

Negative Aug 29, 2026 • 20:23 UTC GlobeNewswire Inc. • The Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. Investors who purchased Disc Medicine securities may be eligible to join a class action lawsuit seeking recovery of losses.

IRON securities class action FDA Complete Response Letter bitopertin program drug approval stock price decline investor losses shareholder litigation

Sentiment note

The company received an FDA Complete Response Letter denying approval of its bitopertin drug application, citing uncertainties requiring additional evidence. This regulatory setback resulted in a 22% stock price decline and triggered a securities class action investigation alleging materially misleading business information to investors.

Negative Aug 29, 2026 • 20:22 UTC GlobeNewswire Inc. • Rosen Law Firm

BellRing Investor News: If You Own Stock in BellRing Brands, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm, a securities litigation firm, is investigating potential fiduciary duty breaches and securities claims against BellRing Brands, Intuit, and Disc Medicine. Current shareholders are encouraged to contact the firm to learn about their legal rights regarding potential losses.

BRBR INTU IRON securities class action fiduciary duty breach shareholder litigation investor rights securities claims

Sentiment note

Company is under investigation for potential securities claims on behalf of shareholders, indicating alleged violations that may have caused investor losses.

Negative Aug 26, 2026 • 00:40 UTC GlobeNewswire Inc. • The Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. Investors who suffered losses are encouraged to join a prospective class action.

IRON securities class action FDA Complete Response Letter bitopertin program stock price decline investor losses new drug application

Sentiment note

The company received an FDA Complete Response Letter denying approval of its bitopertin NDA, indicating regulatory setback and clinical/safety concerns. The 22% stock price decline reflects significant market loss and investor confidence erosion. Securities litigation has been initiated based on allegations of materially misleading business information.

Negative Aug 24, 2026 • 23:18 UTC GlobeNewswire Inc. • Rosen Law Firm

BellRing Investor News: If You Own Stock in BellRing Brands, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential fiduciary duty breaches and securities claims against BellRing Brands, Primoris Services Corporation, and Disc Medicine. The firm is encouraging shareholders who have suffered losses to contact them before important legal deadlines.

BRBR PRIM IRON securities class action fiduciary duty breach shareholder litigation investor losses legal investigation

Sentiment note

Company is subject to investigation for potential securities claims on behalf of shareholders, indicating alleged violations that have harmed investors.

Negative Jul 23, 2026 • 02:51 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Verra Mobility Corporation Investors with Losses to Secure Counsel Before Important August 4 Deadline in Securities Class Action - VRRM

Rosen Law Firm is notifying investors in Verra Mobility Corporation, Microsoft Corporation, and Disc Medicine, Inc. of upcoming deadlines to join securities class action lawsuits. The firm is seeking lead plaintiffs for cases involving alleged materially false statements and concealed material facts, with the primary deadline for Verra Mobility set for August 4, 2026.

VRRM MSFT IRON securities class action lead plaintiff deadline investor losses materially false statements class certification

Sentiment note

Company is subject to ongoing investigation by Rosen Law Firm for potential securities claims on behalf of shareholders, indicating alleged shareholder losses.

Negative Jul 23, 2026 • 00:28 UTC GlobeNewswire Inc. • Rosen Law Firm

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. The stock price fell 22% on the news, and the firm is preparing a class action lawsuit to recover investor losses.

IRON securities class action FDA Complete Response Letter bitopertin program new drug application investor losses stock price decline

Sentiment note

FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin, citing uncertainties requiring additional evidence. The stock price declined 22% on this news, and a securities class action lawsuit is being prepared based on allegations of materially misleading business information to investors.